TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16134519
Drug: Transamin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transamin 0.5 g i.v.
Study: 16134519
Drug: aminomethylbenzoic acid
Normalized name: aminomethylbenzoic acid
DrugBank: Aminomethylbenzoic acid (DB13244)
Approvals — FDA: no, EMA: no, PMDA: no
Description: aminomethylbenzoic acid 0.5 g i.v.
Study: 8048854
Drug: Histamine blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine blocker treatment for hemorrhagic ulcers
Study: 3393383
Drug: Piperacillin 600
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piperacillin 600 mg/kg/day (P)
Study: 3393383
Drug: Piperacillin 600
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piperacillin 600 mg/kg/day plus tobramycin (PT)
Study: 23079690
Drug: Risedronate 35
Normalized name: risedronate 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 35 mg delayed-release (DR) weekly (FB)
Study: 23079690
Drug: Risedronate 35
Normalized name: risedronate 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 35 mg delayed-release (DR) weekly (BB)
Study: 21570934
Drug: Biological causal
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological causal model
Study: 21570934
Drug: Combined causal
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined causal model (biological and psychological)
Study: 1321509
Drug: Enoxaparin, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin, 30 mg subcutaneously every 12 h for up to 14 days
Study: 27509020
Drug: Celgosivir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celgosivir (400 mg loading dose and 200 mg bid over 5 days)
Study: 20685721
Drug: Conventional transcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional transcutaneous electrical nerve stimulation treatment
Study: 7517256
Drug: Oral gammaglobulin
Normalized name: Human gammaglobulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral gammaglobulin (50 mg/kg daily in four divided doses for 28 days)
Study: 2560521
Drug: Conjugated estrogen
Normalized name: Conjugated estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogen (estrone sulfate) at a dose of 1.25 mg/day for 6 weeks
Study: 30355445
Drug: LSD (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD (100 µg po)
Study: 26780757
Drug: Bridging with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bridging with low-molecular-weight heparin during interruption of vitamin K antagonists
Study: 24118931
Drug: Twice-daily premixed
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily premixed protamine-aspart/aspart insulin (PM-2)
Study: 24118931
Drug: Once-daily insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily insulin glargine plus zero to one prandial insulin glulisine injection (G+1)
Study: 24118931
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine plus zero to three prandial injections (G+3)
Study: 19841158
Drug: Silymarin (140,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (140, 280, 560, or 700 mg every 8 hours for 7 days)
Study: 11061613
Drug: CV6504, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CV6504, 100 mg TDS, orally for three months
Study: 1617044
Drug: Cefprozil (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefprozil (500 mg twice daily)
Study: 1617044
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (500 mg twice daily)
Study: 1617044
Drug: Amoxicillin/clavulanate (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (500 mg/125 mg three times daily)
Study: 6143188
Drug: Plasma exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma exchange (5 exchanges in 10 days, 55 ml plasma/kg body weight/exchange)
Study: 29290066
Drug: Tanning behaviors
Normalized name: chlorpheniramine tannate Oral Tablet [Ed Chlor Tan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanning behaviors (indoor tanning, concurrent tanning types)
Study: 23173253
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of meloxicam
Study: 7798511
Drug: Bamiphylline (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bamiphylline (selective antagonist of A1 adenosine receptors)
Study: 3674851
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (500 or 250 mg twice daily) for 7 days
Study: 3674851
Drug: Amoxycillin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (250 mg three times daily)
Study: 29090846
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab 0.5 mg plus laser (COMBI)
Study: 29090846
Drug: Laser monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser monotherapy (LASER)
Study: 26652026
Drug: MD2011001 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: MD2011001 cream
Study: 25109413
Drug: GSK1070806 (0.008
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1070806 (0.008 - 10 mg/kg)
Study: 23543663
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D₃ supplements (Control)
Study: 19787287
Drug: PCD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCD therapy
Study: 11561116
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg daily) in females with primary Raynaud's phenomenon
Study: 11561116
Drug: Nifedipine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (40 mg daily) in females with primary Raynaud's phenomenon
Study: 9115059
Drug: Lidocaine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (10 mg/mL)
Study: 9115059
Drug: Guanethidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanethidine (2 mg/mL)
Study: 9115059
Drug: Nicardipine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (0.2 mg/mL)
Study: 9115059
Drug: Nitroglycerin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (0.3 mg/mL)
Study: 9115059
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (1 microgram/mL)
Study: 24486335
Drug: Oral ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ondansetron 8 mg
Study: 3034469
Drug: Cilazapril 2.5
Normalized name: cilazapril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 2.5 mg/day for 15 days
Study: 31404469
Drug: Osteopathic Manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic Manipulative Therapy (OMTh) for 3 months
Study: 29987329
Drug: CGRP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CGRP infusion (1.5 μg/min over 20 minutes)
Study: 26871700
Drug: Triamcinolone (TA)
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone (TA) 4 mg
Study: 23006898
Drug: Hydrocortisone (stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (stress doses)
Study: 17266687
Drug: Octreotide (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (0.3 mg) administered via continuous intravenous infusion for 6 hours, starting 1 hour before ERCP, with additional subcutaneous injections of 0.1 mg at 6 and 12 hours after infusion stopped.
Study: 17266687
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously.
Study: 9469172
Drug: Attention/support control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attention/support control treatment
Study: 8593922
Drug: Des(64,65)-proinsulin (DPRO)
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: Des(64,65)-proinsulin (DPRO) at doses of 0.1, 0.15, 0.2 U/kg
Study: 8593922
Drug: NPH-insulin at
Normalized name: Neutral Protamine Hagedorn (NPH) insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH-insulin at doses of 0.2, 0.3, 0.4 U/kg
Study: 1115339
Drug: AH 8165,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AH 8165, 1 times 25 mg/kg
Study: 1115339
Drug: Suxamethonium, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium, 1 mg/kg
Study: 25497244
Drug: Warfarin (continuing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (continuing on VKA)
Study: 25497244
Drug: Warfarin (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (for warfarin-naive patients)
Study: 23381685
Drug: Transdiagnostic cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic cognitive‐behavioral therapy intervention (up to 18 weeks)
Study: 19658033
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment received
Study: 16372352
Drug: Inhaled recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled recombinant human alpha(1)-antitrypsin (rAAT) 500 mg
Study: 16372352
Drug: Inhaled recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled recombinant human alpha(1)-antitrypsin (rAAT) 250 mg
Study: 16372352
Drug: Inhaled recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled recombinant human alpha(1)-antitrypsin (rAAT)
Study: 14526711
Drug: Acupuncture; details
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture; details on dosage and duration not available.
Study: 10539706
Drug: Spira Elektro
Normalized name: Lavandula spica oil
DrugBank: Lavender oil (DB14566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spira Elektro 4 jet nebulizer with budesonide (0.5 mg)
Study: 10539706
Drug: Spira Ultra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spira Ultra ultrasonic nebulizer with budesonide (0.5 mg)
Study: 10539706
Drug: Spira Elektro
Normalized name: Lavandula spica oil
DrugBank: Lavender oil (DB14566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spira Elektro 4 jet nebulizer with terbutaline (5.0 mg)
Study: 10539706
Drug: Spira Ultra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spira Ultra ultrasonic nebulizer with terbutaline (5.0 mg)
Study: 6846920
Drug: Albuterol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (100 and 200 micrograms)
Study: 30255204
Drug: Posterior pillar
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior pillar mucosal suspension technique (Group A)
Study: 18823336
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of glibenclamide and diclofenac
Study: 17155990
Drug: Neoadjuvant hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant hormone therapy (HT)
Study: 3137605
Drug: DL-threo-3,4-dihydroxyphenylserine (DOPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL-threo-3,4-dihydroxyphenylserine (DOPS) 1 g dose
Study: 25989386
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment before hemodynamic control
Study: 25989386
Drug: Responders to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responders to medical treatment
Study: 25989386
Drug: Nonresponders to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonresponders to medical treatment (variceal band ligation)
Study: 25989386
Drug: TIPS and
Normalized name: Burt's Bees Tips and Toes Kit Gift Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIPS and medical treatment
Study: 11063177
Drug: Droperidol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (2.5 mg)
Study: 21160196
Drug: Tropisetron (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron (2.5 mg)
Study: 21160196
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no prophylactic antiemetic treatment)
Study: 15510018
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori antibody testing by ELISA
Study: 15510018
Drug: Immunohistochemical analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunohistochemical analysis with H. pylori antibody
Study: 15510018
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of H. pylori antibodies by ELISA
Study: 2529048
Drug: Intranasal sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal sufentanil (15 micrograms)
Study: 2529048
Drug: Intravenous sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sufentanil (15 micrograms)
Study: 30394507
Drug: Atherectomy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atherectomy treatment in diabetic patients (DM)
Study: 30394507
Drug: Atherectomy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atherectomy treatment in non-diabetic patients (nDM)
Study: 25555381
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) administration of Zostavax
Study: 25555381
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) administration of Zostavax
Study: 17112693
Drug: Psidii guajavae
Normalized name: Psidium guajava extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psidii guajavae folium extract 6 mg/day
Study: 17112693
Drug: Psidii guajavae
Normalized name: Psidium guajava extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psidii guajavae folium extract 3 mg/day
Study: 17112693
Drug: Placebo 3
Normalized name: placebo 330 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 3 mg/day
Study: 15086613
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment group (P)
Study: 3067313
Drug: Acetazolamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (250 mg 4 times per day)
Study: 3067313
Drug: Protriptyline (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protriptyline (20 mg daily)
Study: 15563538
Drug: Indomethacin (COX-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (COX-1 and COX-2 inhibitor)
Study: 21777924
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg/d) for 10 days
Study: 9700950
Drug: Wheat amylase
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat amylase inhibitor (WAI) 4 g
Study: 360819
Drug: Essential amino
Normalized name: Essential amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential amino acids (15.7 g daily for 3 months)
Study: 360819
Drug: Liberal diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal diet (1 g protein/kg body weight)
Study: 31243158
Drug: Tablet-based avatar
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based avatar version of the bear
Study: 28260864
Drug: Dexamethasone 5
Normalized name: dexamethasone 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 5 mg/day or 10 mg/day plus HBO therapy
Study: 28260864
Drug: HBO therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBO therapy as monotherapy
Study: 26198966
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 0.5 mg/kg lidocaine and 0.5 mg/kg ketamine, followed by continuous infusion of lidocaine at 0.5 mg·kg(‐1)·h(‐1) till the end of the operation
Study: 26198966
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion only
Study: 23260855
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptives (ethinyl E2 and desogestrel) for 9 weeks
Study: 23260855
Drug: Transdermal patches
Normalized name: MENTHOL 0.3 g in 100 TOPICAL PATCH [Aroamas Cot Nicotine Transdermal Patches]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patches (ethinyl E2 and norelgestromin) for 9 weeks
Study: 21278401
Drug: Metronidazole (MTZ)
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole (MTZ) single-dose 2 g
Study: 19891046
Drug: Daclizumab induction
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab induction plus low-dose cyclosporine
Study: 15482753
Drug: Piroxicam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (10 mg orally) before embryo transfer in fresh cycles
Study: 15482753
Drug: Piroxicam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (10 mg orally) before embryo transfer in frozen-thawed cycles
Study: 9778615
Drug: Ondansetron (OND)
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron (OND) 8 mg every 6 hours for the first 24 hours (total of 4 doses)
Study: 9778615
Drug: Ondansetron (OND)
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron (OND) 32 mg as a loading dose before cisplatin, total dose for the first 24 hours
Study: 8880045
Drug: Draflazine 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Draflazine 3.5 mg
Study: 2397974
Drug: 10% PVP‐iodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% PVP‐iodine solution and 50% salicylic acid plaster therapy
Study: 7197979
Drug: amezinium (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: amezinium (10 mg i.v.)
Study: 7197979
Drug: norfenefrine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: norfenefrine (10 mg i.m.)
Study: 7197979
Drug: dihydroergotamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: dihydroergotamine (1 mg i.m.)
Study: 19021788
Drug: Therapies published
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapies published as case reports (CRs)
Study: 17556695
Drug: DHA-containing functional
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-containing functional food (300 mg DHA/92-kcal bar; average consumption: 5 bars/wk)
Study: 8822534
Drug: Olanzapine 10
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10 +/- 2.5 mg/day (Olz-M)
Study: 8822534
Drug: Olanzapine 15
Normalized name: olanzapine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 15 +/- 2.5 mg/day (Olz-H)
Study: 8822534
Drug: Haloperidol 15
Normalized name: haloperidol 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 15 +/- 5 mg/day (Hal)
Study: 8822534
Drug: Olanzapine 5
Normalized name: olanzapine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 5 +/- 2.5 mg/day (Olz-L)
Study: 31206808
Drug: TAC-ER 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC-ER 0.15 mg/kg/day based on adjusted body weight (aBW)
Study: 31206808
Drug: TAC-ER 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC-ER 0.15 mg/kg/day based on ideal body weight (IBW)
Study: 29501363
Drug: Paclitaxel (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (80 mg/m2 intravenously weekly for 12 doses) plus carboplatin (area under the curve 6 mg/mL per min, intravenously every 3 weeks, for four cycles) plus veliparib (50 mg orally, twice a day)
Study: 27922288
Drug: Immediate rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate rehabilitation (physical therapy from day 1 to day 84)
Study: 27922288
Drug: Traditional rehabilitation
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional rehabilitation (physical therapy from day 29 to day 84)
Study: 22777673
Drug: Intra-arterial ATP
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial ATP infusions
Study: 22777673
Drug: KCl infusion
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KCl infusion
Study: 22777673
Drug: Combined infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined infusion of ouabain and barium chloride (BaCl2)
Study: 22777673
Drug: Combined ouabain
Normalized name: ouabain
DrugBank: Ouabain (DB01092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined ouabain plus BaCl2 infusion
Study: 17568245
Drug: Red yeast
Normalized name: red yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red yeast rice (600 mg, twice daily for 8 weeks)
Study: 9973020
Drug: Forced diuresis
Normalized name: benzalkonium chloride Topical Solution [Clean Force]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forced diuresis with intravenous crystalloid, furosemide, mannitol (if pulmonary capillary wedge pressure <20 mm Hg), and low-dose dopamine (n = 43)
Study: 9973020
Drug: Intravenous crystalloid
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous crystalloid and matching placebos (n = 55)
Study: 7072998
Drug: No inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No inhalation agent (Group 1)
Study: 31225821
Drug: Theta burst
Normalized name: Coptis teeta root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theta burst repetitive transcranial magnetic stimulation (active treatment)
Study: 31225821
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control (sham treatment)
Study: 19251584
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (440 microg twice daily)
Study: 17237724
Drug: Folate supplementation
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate supplementation in combination with other treatments for IBD
Study: 15764422
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg and 40 mg)
Study: 7988776
Drug: 7-hour local
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-hour local hyperglycaemia (5% glucose infusion)
Study: 2971693
Drug: Topical isotretinoin
Normalized name: isotretinoin Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical isotretinoin (0.05%)